Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

monoclonal antibody BIWA 4

Known as: BIWA 4 (MAb), bivatuzumab 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
SHIZENGAKU [BIWA/BIWAKO]: SONIC COMPLEMENT, COUNTERPOINT OR INTERPENETRATION?
This copy has been supplied on the understanding that it is copyright material. Duplication or sale of all or part of any of the… Expand
2013
2013
Drug targeting , Pharmacokinetics and Biodistribution : Differences between species
SUMMARY Hyaluronan (HA)-binding proteins, such as the cell-surface CD44 proteoglycan family and the Receptor for Hyaluronoan… Expand
Highly Cited
2006
Highly Cited
2006
A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus
Purpose: To assess safety, pharmacokinetics, maximum tolerated dose, and preliminary efficacy of bivatuzumab mertansine… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 4
2006
2006
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
PURPOSE To assess safety, pharmacokinetics, maximum tolerated dose, and preliminary efficacy of bivatuzumab mertansine… Expand
2004
2004
Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer.
UNLABELLED The aim of this prospective study was to evaluate the safety, pharmacokinetics, immunogenicity, and biodistribution of… Expand
Highly Cited
2003
Highly Cited
2003
Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck
Previous studies have shown the potential of murine and chimeric anti-CD44v6 monoclonal antibodies (MAbs) for radioimmunotherapy… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
2003
2003
Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
UNLABELLED From December 1999 until July 2001, a phase I dose escalation study was performed with (186)Re-labeled bivatuzumab, a… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Review
2003
Review
2003
CD44v6: a target for antibody-based cancer therapy
The human CD44 gene encodes type 1 transmembrane glycoproteins involved in cell-cell and cell-matrix interactions. The structural… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • table 3
2000
2000
TONAI Kakuryo, Nihon kindai biwa no kenkyu: Toriguchi, shirabeguchi wo chushin to shita “sawari” no ongaku kozo
 
1983
1983
Biwa-Hoshi : From the Viewpoint of "Marebito" Theory Part I
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE